HCPLive
2010 American Heart Association (AHA) Scientific Sessions
The AHA 2010 Scientific Sessions are structured around "seven cardiovascular cores that reflect the evolution of scientific investigation and practice; include and integrate basic, clinical, population and translational science."
Day 4
Study shows that cholesteryl ester transfer protein (CETP) inhibitor anacetrapib reduced LDL by 40% and doubled HDL in patients with coronary disease.
Poor medication plan adherence poses major health risks in patients with cardiovascular illnesses. Better adherence starts with better communication.
Post-traumatic stress disorder more than doubles a veteran's risk of death from any cause and is an independent risk factor for cardiovascular disease.
Retrospective analysis reveals that statin use is not associated with increased risk of cancer.
Day 3
Unique treatment using fat-derived stem cells reduced heart tissue damage and improved cardiac blood flow in patients who had suffered a heart attack.
Intravenous treatment with the iron compound ferric carboxymaltose improves health-related quality of life in patients with chronic heart failure.
Once you've determined that a patient truly is statin-intolerant, there are several viable alternatives for lipid-lowering therapy, including niacin.
GRAVITAS trial results show that high-dose clopidogrel does not reduce the incidence of death, heart attack, or blood clots in high-risk patients.
Day 2
Rivaroxaban is as effective as warfarin in preventing blood clots and stroke and does not increase bleeding risk in patients with atrial fibrillation.
MESA trial finds association between lower coronary artery calcium and carotid artery thickness and adherence to AHA "Life's Simple 7" health factors.
Researchers find no benefit from prescription omega-3 in patients with paroxysmal atrial fibrillation who do not have significant heart disease.
Alternate statin-dosing protocol shows significant reductions in LDL and total cholesterol in previously statin-intolerant women.
Day 1
Combining cardiac-resynchronization therapy with medication and an ICD reduces deaths and hospitalizations due to heart failure.
EMPHASIS-HF trial results show eplerenone reduces risk of death and hospitalization by 37% in patients with systolic heart failure.
ASCEND-HF trial shows that previous thinking on nesiritide was wrong: it is safe, but has only modest effect on dyspnea patients with heart failure.
Data from NHANES-III shows that vitamin D deficiency does not increase stroke risk in African American patients.
Scheduling, event, exhibit hall, CME, and other information for attendees of the AHA 2010 Scientific Sessions.
Sign up for HCPLive eNewsletters
*Firstname:
*Lastname:
*Email:
*Practice Type:

Intellisphere, LLC
666 Plainsboro Road
Building 300
Plainsboro, NJ 08536
P: 609-716-7777
F: 609-716-4747

Copyright HCPLive 2006-2011
Intellisphere, LLC. All Rights Reserved.
 




Become a Member